HIV integrase inhibitors

US7538112B2 · kind B2 · utility

Assignee

• MERCK & CO., INC. · US

Inventors

• John S. Wai · Harleysville, US
• Joseph P. Vacca · Telford, US
• Linghang Zhuang · Doylestown, US
• Boyoung Kim · Lexington, US
• Terry A. Lyle · Lederach, US
• Catherine M. Wiscount · Allentown, US
• Melissa Egbertson · Ambler, US
• Lou Anne Neilson · Sellersville, US
• Mark W. Embrey · North Wales, US
• Thorsten E. Fisher · Hatfield, US
• Donnette D. Staas · Harleysville, US

Key dates

• Filing date: May 3, 2005
• Grant date: May 26, 2009
• Expiry date: Jun 21, 2026

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Hydroxy-substituted pyrazinopyrrolopyridazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.